Xonvea Magasýruþolin tafla 10 mg/10 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

xonvea magasýruþolin tafla 10 mg/10 mg

campuspharma ab - pyridoxinum hýdróklóríð; doxylaminii hýdrógen súkkínat - magasýruþolin tafla - 10 mg/10 mg

Sunitinib Accord Evrópusambandið - íslenska - EMA (European Medicines Agency)

sunitinib accord

accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Unituxin Evrópusambandið - íslenska - EMA (European Medicines Agency)

unituxin

united therapeutics europe ltd - dinutuximab - neuroblastoma - Æxlishemjandi lyf - unituxin er ætlað fyrir meðferð hár-hættu taugakímfrumuæxli í sjúklinga á aldrinum 12 mánuði að 17years, sem hafa áður fengið framkalla lyfjameðferð og náð að minnsta kosti að hluta svar, eftir myeloablative meðferð og samgena stafa klefi ígræðslu (asct). Það er gefið í samsettri meðferð með kólesteról-kólesteról-örvandi þáttum (gm-csf), interleukin-2 (il-2) og ísótretínóín.

Sutent Evrópusambandið - íslenska - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Æxlishemjandi lyf - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Altargo Evrópusambandið - íslenska - EMA (European Medicines Agency)

altargo

glaxo group ltd - retapamulin - impetigo; staphylococcal skin infections - sýklalyf og krabbameinslyf til dýrafræðilegrar notkunar - short term treatment of the following superficial skin infections: , impetigo;, infected small lacerations, abrasions or sutured wounds. , sjáðu kafla 4. 4 og 5. 1 fyrir mikilvægar upplýsingar varðandi klínískum virkni retapamulin gegn mismunandi tegundir af Þegar sýkt merkið bit. Íhuga ætti að opinbera leiðsögn á réttri notkun af sýklalyfjum.

Imoxat Evrópusambandið - íslenska - EMA (European Medicines Agency)

imoxat

chanelle pharmaceuticals manufacturing ltd - imidacloprid, moxidectin - antiparasitic products, insecticides and repellents, macrocyclic lactones, milbemycins - cats; dogs; ferrets - for cats suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of ear mite infestation (otodectes cynotis),• the treatment of notoedric mange (notoedres cati),• the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),• the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),• the treatment of the lungworm aelurostrongylus abstrusus (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme). dýralyfið er hægt að nota sem hluti af meðferðaráætlun fyrir húðsjúkdóm í húðflóa (fad).  for ferrets suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis).  for dogs suffering from, or at risk from, mixed parasitic infections:• the treatment and prevention of flea infestation (ctenocephalides felis),• the treatment of biting lice (trichodectes canis),• the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),• the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),• the treatment of circulating microfilariae (dirofilaria immitis),• the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)• the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),• the reduction of circulating microfilariae (dirofilaria repens),• the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),• the treatment of angiostrongylus vasorum and crenosoma vulpis,• the prevention of spirocercosis (spirocerca lupi),• the treatment of eucoleus (syn. capillaria) boehmi (adults),• the treatment of the eye worm thelazia callipaeda (adults),• the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis). dýralyfið er hægt að nota sem hluti af meðferðaráætlun fyrir húðsjúkdóm í húðflóa (fad).

Glybera Evrópusambandið - íslenska - EMA (European Medicines Agency)

glybera

uniqure biopharma b.v.  - alipogene tiparvovec - hyperlipoproteinemia type i - lipid breytandi lyf - glybera er ætlað til fullorðinna sjúklinga sem greinast með ættgengri lípópróteinlipasa skort (lpld) og þjást af alvarlegum eða mörgum brisbólguárásum þrátt fyrir mataræði. greining lpld þarf að staðfesta með erfðafræðilegri prófun. vísbendingin er takmörkuð við sjúklinga með greinanlegan magn af lpl próteinum.